OMB Proposes Overhaul of Federal Research Grants, Shifting Power from Peer Review to Political Appointees

The public comment period closes today on a sweeping federal proposal that could fundamentally rewire how the United States funds scientific, medical, and educational research. In late May 2026, the Office of Management and Budget (OMB) released the "Regulation for Federal Financial Assistance," initiating a 45-day review window that has drawn intense scrutiny from across the academic spectrum. The proposed rule represents a comprehensive rewrite of 2 CFR Part 200, commonly known as the uniform guidance, which serves as the primary regulatory framework governing federal grantmaking. If implemented in its current form, the regulation would shift the balance of power in federal funding away from independent subject-matter experts and toward executive branch officials, altering a system that has underpinned American innovation for decades.[2][4]

At the heart of the proposal is a structural change to the grant approval mechanism that governs hundreds of billions of dollars in annual discretionary funding. Since the end of World War II, federal agencies have relied heavily on merit-based peer review—a system where independent scientists, academics, and industry experts evaluate grant proposals based on their technical rigor, feasibility, and potential public benefit. This decentralized approach was designed to insulate scientific inquiry from political interference, ensuring that taxpayer dollars flow to the most promising and methodologically sound projects regardless of the prevailing political climate.[1][3]

Under the new OMB rule, these longstanding peer review recommendations would be explicitly designated as "advisory" rather than binding. Final approval for discretionary grants would instead require a mandatory "pre-issuance review" conducted by senior political appointees or their designated representatives. This shift fundamentally changes who has the final say on which scientific endeavors receive taxpayer support, moving the ultimate decision-making authority from panels of specialized researchers to officials appointed by the White House. Agencies would no longer be required to issue awards solely based on scientific merit scores, fundamentally altering the competitive landscape of federal research.[4]

These appointed officials would be tasked with evaluating whether a proposed research project demonstrably advances the President's policy priorities and aligns with the broader national interest before any funds are disbursed to universities or laboratories. Administration officials argue this overhaul is a necessary step to bring accountability to a sprawling grant system that distributes massive amounts of taxpayer dollars annually across thousands of disparate projects. OMB Director Russell Vought and other proponents maintain that executive oversight is required to ensure federal funds are spent wisely, efficiently, and in direct service of the administration's strategic goals, rather than being captured by insular academic interests that may not reflect the priorities of the voting public.[1][2][4]

Proponents of the rule point to instances of federal funds supporting controversial social research—such as projects involving diversity, equity, and inclusion initiatives, or studies that challenge the biological sex binary—as evidence that domain experts alone cannot be trusted with final financial oversight. They also cite national security concerns, pointing to past sub-grants awarded to the Wuhan Institute of Virology, arguing that tighter executive control is necessary to prevent funds from flowing to adversarial nations. By elevating executive review, the administration aims to ensure that federal financial assistance is not wasted on low-quality proposals or projects that conflict with broader national security and economic objectives.[1][4]

However, the proposal has triggered a massive and highly coordinated mobilization across the academic, scientific, and medical communities. By mid-July, the Federal Register had logged nearly 100,000 public comments, with the vast majority expressing deep concern over the potential politicization of science. A coalition of 49 higher education associations, led by the American Council on Education (ACE), submitted formal comments warning that the rule would replace scientific rigor with ideological alignment. The coalition, which includes the Association of American Universities and the Association of Public and Land-grant Universities, argues that the credibility of American research hinges entirely on insulating funding decisions from shifting political winds and partisan agendas.

Academic leaders warn that politicizing the grant process will stifle innovation, deter early-career researchers from pursuing groundbreaking science, and ultimately threaten the United States' position as a global technological leader. Beyond the shift in approval authority, the rule grants federal agencies expanded power to suspend or terminate active grants mid-cycle. Under the proposal, an agency could cancel a grant "for convenience" if the project is deemed inconsistent with evolving agency priorities or the national interest. This represents a stark departure from current norms, where grants are typically only revoked for severe scientific misconduct, financial mismanagement, or a failure to meet the agreed-upon research deliverables.[2][3][4]

Medical researchers and patient advocacy groups have raised severe alarms about this specific termination provision. They note that multi-year longitudinal studies, disease surveillance programs, and complex clinical trials could be abruptly canceled without any finding of poor performance, wasting years of irreplaceable data and potentially endangering human participants. For example, researchers studying chronic conditions like Long COVID or conducting decades-long cancer screenings rely heavily on stable, predictable funding that spans multiple presidential administrations. The threat of sudden cancellation could make it impossible to recruit participants or retain specialized laboratory staff for these vital public health initiatives.[1][3]

The proposal also eliminates the administrative hearing process for terminated grants, removing a critical layer of due process for research institutions. This change would leave costly and time-consuming litigation as the only recourse for researchers and universities whose funding is suddenly pulled by an agency. Without an internal appeals process, universities fear they will have no practical way to contest arbitrary cancellations, creating a chilling effect on ambitious, long-term scientific inquiries that might touch on politically sensitive topics like climate science or public health policy.[4]

Additional provisions in the rule place strict limits on how grant funds can be utilized by researchers on a day-to-day basis. The proposal restricts the use of federal money for open-access publication fees, academic journal subscriptions, and conference attendance unless those expenses are expressly pre-approved by the funding agency. Critics argue this adds a new layer of bureaucratic friction to the dissemination of scientific discoveries, making it harder for researchers to share their findings with the global scientific community and collaborate with peers at academic conferences.[4]

The rule also introduces broad new restrictions on international collaboration, explicitly barring federal funds from supporting partnerships with entities in countries deemed adversarial to the United States, such as China and Russia. It adds stringent new reporting requirements for foreign researchers working domestically, which universities warn could isolate American scientists from the global research network. Administrators argue that requiring a small number of political appointees to personally review thousands of highly technical grant applications will inevitably lead to massive delays in funding distribution, paralyzing laboratories that rely on predictable grant cycles to pay graduate students and purchase specialized equipment.[1][3][4]

With the public comment period closing on July 13, the OMB is required by the Administrative Procedure Act to review the submitted feedback before issuing a final regulation. The administration has stated its intention to finalize the rule by October 1, 2026, setting the stage for a potential legal showdown between the executive branch and the nation's leading research institutions. As that deadline approaches, the higher education community is bracing for a fundamental shift in the research landscape, warning that the new regulations could permanently alter the trajectory of American scientific dominance.[1][2]